M1 Muscarinic Agonists Can Modulate Some of the Hallmarks in Alzheimer's Disease: Implications in Future Therapy

Journal of Molecular Neuroscience

Volumn 20, Issue 3, 2003, Pages 349-356

  Fisher, Abraham ^a   Pittel, Zipora ^a   Haring, Rachel ^a   Bar Ner, Nira ^a   Kliger Spatz, Michal ^a   Natan, Niva ^a   Egozi, Inbal ^a   Sonego, Hagar ^a   Marcovitch, Itzhak ^a   Brandeis, Rachel ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

APPs; amyloid; Alzheimer's disease; Animal models; Apoptosis; Cell death; M1 agonist; Tau proteins

Indexed keywords

3 [3 (3 METHOXYPHENYL) 2 PROPYNYLOXYIMINO] 1 AZABICYCLO[2.2.1]HEPTANE; AC 90222; ACC 90222; AF 150 S; AF 267 B; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[25-35]; AMYLOID PRECURSOR PROTEIN; ANTIINFLAMMATORY AGENT; BETA SECRETASE INHIBITOR; CARBACHOL; CEVIMELINE; CHOLINESTERASE INHIBITOR; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; HYDROXYCHLOROQUINE; MILAMELINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINE; NICOTINIC AGENT; PHYSOSTIGMINE; RIVASTIGMINE; TALSACLIDINE; TAU PROTEIN; UNCLASSIFIED DRUG; (S) 2 ETHYL 8 METHYL 1 THIA 4,8 DIAZASPIRO(4.5)DECAN 3 ONE; (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO(4.5)DECAN-3-ONE; 1 METHYLPIPERIDINE 4 SPIRO (2' METHYLTHIAZOLINE); 1-METHYLPIPERIDINE-4-SPIRO-(2'-METHYLTHIAZOLINE); PIPERIDINE DERIVATIVE; QUINUCLIDINE DERIVATIVE; SPIRO COMPOUND; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BEHAVIOR; BRAIN SIZE; CELL CULTURE; CELL DEATH; CELL VIABILITY; CEREBROSPINAL FLUID; CHOLINERGIC SYSTEM; COGNITION; COGNITIVE DEFECT; DISEASE ASSOCIATION; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; ENZYME ACTIVATION; ESCAPE BEHAVIOR; HIPPOCAMPUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LABORATORY; LATENT PERIOD; LEARNING; LONG TERM CARE; MAZE TEST; MODULATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PAIRED HELICAL FILAMENT; PARKINSON DISEASE; PRESCRIPTION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RABBIT; SJOEGREN SYNDROME; ANIMAL; BIOSYNTHESIS; BRAIN; DISEASE MODEL; DOWN REGULATION; DRUG ANTAGONISM; MEMORY DISORDER; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ALIA; ANIMALIA; ORYCTOLAGUS CUNICULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CELL DEATH; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HUMANS; MEMORY DISORDERS; MICE; MUSCARINIC AGONISTS; OXIDATIVE STRESS; PIPERIDINES; QUINUCLIDINES; RECEPTOR, MUSCARINIC M1; SPIRO COMPOUNDS; TAU PROTEINS; THIAZOLES; THIOPHENES;

EID: 0642340251     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:20:3:349     Document Type: Article

References (31)

1. Beach T. G., Potter P. E., Sue L. I., Fisher A., Scott S., Layne K. J., et al. (2002) Cerebral Abeta deposition induced by cortical deafferentation is reduced by cholinergic therapy. Soc. Neurosci. Abstr. 722, 9.
2. Beach T. G., Walker D. G., Potter P. E., and Fisher A. (2001) Reduction of cerebrospinal fluid amyloid beta after systemic administration of Ml muscarinic agonists. Brain Res. 905, 220-223.
3. Buxbaum J. D., Oishi M., Chen H. I., Pinkas-Kramarski R., Jaffe E. A., Gandy S. E., and Greengard P. (1992) Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta-A4 amyloid protein precursor. Proc. Natl. Acad. Sci. USA 89, 10,075-10,078.
4. Eckols K., Bymaster F. P., Mitch C. H., Shannon H. E., Ward J. S., and DeLapp N. W. (1995) The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from CHOM1 cells. Life Sci. 57, 1183-1190.
5. Fisher A. (1997) Muscarinic agonists for the treatment of Alzheimer's disease: progress and perspectives. Exp. Opin. Invest. Drugs 6, 1395-1414.
6. Fisher A. (1999) Muscarinic receptor agonists in Alzheimer's disease. More than just symptomatic treatment. CNS Drugs 12, 197-214.
7. Fisher A. (2000) Therapeutic strategies in Alzheimer's Disease: M1 muscarinic agonists. Jpn. J. Pharmacol. 84, 101-112.
8. Forlenza O. V., Spink J. M., Dayanandan R., Anderton B. H., Olensen O. F., and Lovestone S. (2000) Muscarinic agonists reduce τ phosphorylation in non-neuronal cells via GSK-3β inhibition and in neurons. J. Neural Transm. 107, 1201-1212.
9. Genis I., Fisher A., and Michaelson D. M. (1999) Site-specific dephosphorylation of tau in apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment. J. Neurochem. 12, 206-213.
10. Haring R., Fisher A., Marciano D., Pittel Z., Kloog Y., Zuckerman A., et al. (1998) Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the M1 muscarinic receptor to amyloid precursor protein secretion. J. Neurochem. 71, 2094-2103.
11. Haring R., Gurwitz D., Barg J., Pinkas-Kramarski R., Heldman E., Pittel Z., et al. (1994) Amyloid precursor protein secretion via muscarinic receptors: Reduced desensitization using the M1-selective agonist AF102B. Biochem. Biophys. Res. Comm. 203, 652-658.
12. Haring R., Gurwitz D., Barg J., Pinkas-Kramarsky R., Heldman E., Pittel Z., et al. (1995) NGF promotes amyloid protein secretion via muscarinic receptor activation. Biochem. Biophys. Res. Comm. 213, 15-23.
13. 1 muscarinic agonists protect PC12M1 cells from growth factor deprivation and beta-amyloid-induced apoptosis. World Conference on Alzheimer's Disease, Washington, D.C., July 9-13.
14. Hartmann T., Runz H., Grimm H., Grziwa B., Bergmann C., Simons M., et al. (2002) γ-Secretase inhibition via cholesterol depletion involves presenilin. Soc. Neurosci. Abstr. 122, 6.
15. Hellstrom-Lindahl E., Moore H., and Nordberg A. (2000) Increased levels of T protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J. Neurochem. 74, 777-784.
16. Hock C., Maddalena A., Heuser I., Naber D., Oertel W., von Der Krame H., et al. (2000) Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease. Ann. N.Y. Acad. Sci. 920, 285-291.
17. Hung A. Y., Haass C., Nitsch R., Qiu W. Q., Citron M., Wurtman R. J., et al. (1993) Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J. Biol. Chem. 268, 22,959-22,962.
18. Kurumatani T., Fastbom J., Bonkale W. L., Bogdanovic N., Winblad B., Ohm T. G., and Cowburn R. F. (1998) Loss of inositol 1,4,5-trisphosphate receptor sites and decreased PKC levels correlate with staging of Alzheimer's disease neurofibrillary pathology. Brain Res. 796, 209-221.
19. Leloup C., Michaelson D. M., Fisher A., Hartmann T., Beyreuther K., and Stein R. (2000) M1 muscarinic receptors blocks caspase activation by phosphatidylinositide 3-kinase and MAPK/ERK-independent pathways. Cell Death Differ. 7, 825-833.
20. Lucas J., Hernandez F., Gomez-Ramos P., Moran M. A., Hen R., and Avila J. (2001) Decreased nuclear β-catenin, τ hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J. 20, 27-39.
21. Mattson M. P. (1997) Central role of oxyradicals in the mechanism of amyloid beta-peptide cytotoxicity. Alzheimer's Dis. Rev. 2, 1-14.
22. Muller D. M., Mendla K., Farber S. A., and Nitsch R. M. (1997) Muscarinic Ml receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sci. 60, 985-991.
23. Nitsch R. M., Deng M., Tennis M., Schoenfield D., and Growdon J. H. (2000) The selective muscarinic M1 agonist AF102B decreases levels of total A (beta) in cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 48, 913-918.
24. Nitsch R. N., Slack B. E., Wurtman R. J., and Growdon J. H. (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 58, 304-307.
25. Perry E. K., Burn D. J., Kilford L., Lees A. J., and Perry R. H. (2002) Increased Alzheimer pathology in Parrkinson's disease is associated with chronic antimuscarinic drug treatment. Seventh International Meeting on Parkinson Disease and Movement Disorders, Nov., Miami FL.
26. Pittel Z., Heldman E., Barg J., Haring R., and Fisher A. (1996) Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum. Brain Res. 742, 299-304.
27. Sadot E., Gurwitz D., Barg J., Behar L., Ginzburg I., and Fisher A. (1996) Activation of ml-muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J. Neurochem. 66, 877-880.
28. 1 subtype selective muscarinic agonists for Alzheimer's disease: Translation of in vitro selectivity into in vivo efficacy. Drug Dev. Res. 40, 133-143.
29. Simons M., Schwarzler F., Lutjohann D., von Bergmann K., Beyreuther K., Dichgans J., et al. (2002) Treatment with simavastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 52, 346-350.
30. 1 agonist, enhanced spatial learning in C57BL/10 mice with a long duration of action. Brain Res. 597, 264-268.
31. Wolf B. A., Wertkin A. M., Jolly Y. C., Yasuda R. O., Wolfe B. B., Konrad R. J., et al. (1995) Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. J. Biol. Chem. 270, 4916-4922.